Can-Fite BioPharma Ltd. CANF
1.66 USD +0.04 (+2.47%)
Nov 9, 2026, 12:16 PM EST
1.60 Day range 1.69
1.50 52-week range 12.40
- YTD
- -58.50%
- 1 year
- -79.76%
News
benzinga.com Can-Fite Announces 10-Yr Cancer-Free Survival In Advanced Liver Cancer Patient Treated With Namodenoson Patient from the Company’s completed Phase II study remains cancer-free and in good health at the ten-year survival milestoneRamat Gan, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma…
benzinga.com Can-Fite Biopharma To Pursue Global Licensing And Strategic Partnerships Using Its Phase IIa Pancreatic Cancer Results Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced its…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 16.2% to $4.67 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Cerus…
benzinga.com Can-Fite BioPharma Says EAPO Issues Notification Of Readiness To Grant Patent Covering Use Of Piclidenoson For Treatment Of Diseases Associated With OCRL Deficiency Allowed claims cover Lowe syndrome and Dent disease 2; Can-Fite holds development, commercialization, and out-licensing rights for these indications under its agreement with Fondazione TelethonRamat…
globenewswire.com Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome Allowed claims cover Lowe syndrome and Dent disease 2; Can-Fite holds development, commercialization, and out-licensing rights for these indications under its agreement with Fondazione Telethon Ramat…
benzinga.com Can-Fite Presents Phase IIa Namodenoson Data In Advanced Pancreatic Cancer, Meeting Primary Safety Endpoint And Showing Encouraging Survival Outcomes Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patientsOne second-line patient achieved progression-free survival of 16.39 months…
benzinga.com Can Fite Biofarma H1 EPS $(1.24) Beats $(1.43) Estimate, Sales $202.000K, Same YoY Can Fite Biofarma (AMEX:CANF) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.43) by 13.29 percent. This is a 71.1 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers bioAffinity Technologies (NASDAQ:BIAF) stock moved upwards by 54.3% to $10.17 during Wednesday's regular session. The company's market cap stands at $3.9 million. Gelteq (NASDAQ:GELS) shares…
benzinga.com Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study Can-Fite BioPharma reports longer survival in its Phase 3 liver cancer trial and raises $4 million through a warrant exercise.
benzinga.com Can-Fite BioPharma To Receive ~$4M From Exercise Of 1,591,738 Warrants At Reduced $2.50/ADS Price Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF) ("Can-Fite" or the "Company"), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Can Fite Biopharma (AMEX:CANF) shares moved upwards by 20.4% to $3.96 during Wednesday's pre-market session. The company's market cap stands at $7.0 million. Aligos Therapeutics (NASDAQ:ALGS)…- benzinga.com Can-Fite Says Blinded Overall Survival Observed Across Entire Patient Population In Ongoing Pivotal Phase III Study Of Namodenoson In Advanced HCC Appears Longer Than Originally Anticipated Based On Assumptions Underlying Study Design Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases,…
benzinga.com Can-Fite BioPharma Announces New Preclinical Findings Demonstrating Namodenoson Enhances Anti-Cancer Effect Of Gemcitabine Chemotherapy In Pancreatic Cancer The New Mechanistic Findings Support Can-Fite’s Ongoing Phase IIb Study Design Following Positive Phase IIa ResultsRamat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.…- benzinga.com Can-Fite BioPharma Submits Phase 2 Clinical Study Protocol To Bambino Gesù Children's Hospital In Rome, Italy, For First Clinical Evaluation Of Piclidenoson In Patients With Lowe Syndrome Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory interactions and potential registration upon positive resultsRamat Gan, Israel, Aug. 03, 2026 (GLOBE…
- benzinga.com Can-Fite Pancreatic Cancer Data Accepted For ESMO Presentation, To Present Namodenoson Cancer Study Results At The Event Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases,…
- benzinga.com Can-Fite BioPharma Completes Enrolment Of First 247 Patients In Pivotal Phase 3 Study Evaluating Piclidenoson For Treatment Of Moderate-To-Severe Plaque Psoriasis Interim analysis to be conducted under an FDA- and EMA-agreed protocolRamat Gan, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage…
- benzinga.com 11 Health Care Stocks Moving In Thursday's Intraday Session Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's regular session. The market value of their outstanding shares is at $12.2 million. Liminatus Pharma…
benzinga.com HC Wainwright & Co. Reiterates Buy on Can Fite Biopharma, Raises Price Target to $8 HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Can Fite Biopharma (AMEX:CANF) with a Buy and raises the price target from $5 to $8.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Can Fite Biopharma (AMEX:CANF) shares rose 43.8% to $4.27 during Wednesday's regular session. The company's market cap stands at $6.3 million. Regencell Bioscience (NASDAQ:RGC) stock moved…
benzinga.com Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients Can-Fite's Phase 2a Namodenoson study met its safety endpoint and showed durable survival, supporting a Phase 2b chemotherapy trial.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's pre-market session. The company's market cap stands at $6.3 million. Atlantic International…
benzinga.com Market-Moving News for July 1st NKE: -9% | Nike shares are trading lower. The company reported Q4 financial results. BE: 12% | Bloom Energy shares are trading higher after the company announced it expanded its AI infrastructure…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi…
benzinga.com Can-Fite Stock Jumps After Japan Patent Boosts Obesity Drug Case Can-Fite stock rises after Japan patent allowance strengthens Namodenoson’s obesity and metabolic disease opportunity.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Quantum Cyber (NASDAQ:QUCY) stock moved upwards by 63.4% to $2.37 during Friday's pre-market session. The company's market cap stands at $33.0 million. INVO Fertility (NASDAQ:IVF) shares…
- benzinga.com Market-Moving News for June 26th ON: -14% | ON stock has given up its prior gain. ON Semiconductor shares were trading higher after the company announced it will acquire Synaptics. IVF: 84% | INVO Fertility Acquires HRCFG For…
- benzinga.com Can-Fite BioPharma Announces Japan Patent Allowance Covering Namodenoson’s Anti‑Obesity Activity The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and further supports Namodenoson's positioning in obesity and metabolic diseasesRamat Gan, Israel, June…
- benzinga.com Can-Fite BioPharma Announces Publication Of Peer-Reviewed Scientific Article Showing Broad Therapeutic Potential Of Lead Drug Candidates, Piclidenoson And Namodenoson, Across Multiple Major Diseases Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced…
- benzinga.com Can-Fite Highlights Pancreatic Cancer Drug Progress Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory…
benzinga.com Can-Fite BioPharma Announces Publication Of Peer-Reviewed Scientific Article On Findings From Study Evaluating Piclidenoson For Treatment Of Canine Osteoarthritis Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced…- benzinga.com D. Boral Capital Upgrades Can Fite Biopharma to Buy, Announces $7 Price Target D. Boral Capital analyst Jason Kolbert upgrades Can Fite Biopharma (AMEX:CANF) from Hold to Buy and announces $7 price target.
- benzinga.com Can-Fite BioPharma Plans To Advance Pancreatic Cancer Program Into Phase 2b Study Evaluating Namodenoson In Combination With Immunotherapy In Patients With Advanced Pancreatic Cancer Phase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advances partnership negotiations with leading oncology companiesRamat Gan, Israel, May 13, 2026 (GLOBE…
- benzinga.com HC Wainwright & Co. Maintains Buy on Can Fite Biopharma, Raises Price Target to $5 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Can Fite Biopharma (AMEX:CANF) with a Buy and raises the price target from $2.5 to $5.
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Can-Fite BioPharma Announces Its Phase 2a Trial Of Namodenoson In Advanced Pancreatic Cancer Participants Demonstrates Over 30% Of Patient Had Stable Disease Observed, Preliminary Evidence Of Clinical Activity, Favorable Safety And Tolerability Profile Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory…
- benzinga.com Can-Fite Biopharma's Veterinary Partner Vetbiolix Completes Enrollment In Phase 2 Study Of Piclidenoson For Osteoarthritis In Dogs; Topline Data Are Expected In Q3 2026 Vetbiolix, Can-Fite's veterinary commercialization partner, is funding all development costs associated with the registration of Piclidenoson for osteoarthritis in companion animals.Vetbiolix has…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Nasdaq Surges Over 1%; ISM Services PMI Tops Views U.S. stocks up on Wednesday with NASDAQ gaining 0.85%. ISM services PMI rose to 56.1. VCI Global Ltd, Latham Group Inc, and Can Fite Biopharma surge.
benzinga.com Dow Surges 100 Points; Abercrombie & Fitch Shares Fall After Q4 Results US stocks rise, with Dow up 0.25% and NASDAQ up 0.69%. Consumer discretionary shares increase by 1.1%, while energy stocks dip by 0.6%.- benzinga.com Market-Moving News for March 4th MRNA: 11% | Moderna shares are trading higher after the company announced that it has entered into a settlement agreement with Arbutus Biopharma and Genevant Sciences. CANF: 54% | Can-Fite
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Why Aptevo Therapeutics Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Friday's Mid-Day Session - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session